Amgen Sued Over Proposed Opdivo Biosimilar as BMS Defends Blockbuster Cancer Drug
Amgen is facing a lawsuit over its proposed Opdivo biosimilar. The move comes as Bristol Myers Squibb (BMS) seeks to defend its blockbuster cancer drug, Opdivo.
The lawsuit was filed in response to Amgen's efforts to bring a biosimilar version of Opdivo to market. Biosimilars are generic versions of complex biologic medications like Opdivo.